Skip To Main Content
Maaisha Osman on Muck Rack

Maaisha Osman

Verified
Washington, D.C.
As seen in: Citeline, The Pink Sheet, STAT, NewsBreak, Online News Association, BioSpace, Spectrum, Generics Bulletin, Scrip, Medtech Insight, Bay State Banner, Inside U.S. Trade and
health policy reporter @PharmaPinkSheet • cinephile signal: maaisha.07 Send tips to maaisha.osman@citeline.com
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Maaisha

Contact Maaisha, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Trump’s Largely Redacted Drug Pricing Deal Docs Include A Decade of Undisclosed Terms

|
By Maaisha Osman Verified
| The Pink Sheet Verified
The redacted documents Public Citizen obtained via FOIA offered little information about many important provisions, such as the drugs covered, price setting process and overseas revenue flow back to the US, but made clear they will remain secret for at least a decade after the deals expire. HHS pledged to keep Pfizer's deal terms confidential for at least 10 years after the agreement expires. (Joyce N.
Open in Who Shared Issue with article?

CDER Director Mike Davis Eyes AI As Solution To Institutional Memory Loss

|
By Maaisha Osman Verified
| HBW Insight Podcasts
FDA's drug review chief wants artificial intelligence to do what regulators can no longer do after a wave of retirements: remember every decision the agency has ever made. CDER Director Mike Davis said the vast majority of center staff are already using AI regularly in their work.
Open in Who Shared Issue with article?

Medicaid GENEROUS Model Gets All States To Participate As Key Details Remain Unclear

|
By Maaisha Osman Verified
| The Pink Sheet Verified
The GENEROUS pilot is a closed club – limited to the 26 drug makers that already struck MFN deals with the Trump administration. The program's prices, and even which products are part of it, are still undisclosed. President Trump hails a drug pricing milestone. Analysts see it as the end of the line for pharma concessions. (Shutterstock) Key Takeaways As of Sept. 18, all 50 states have agreed to participate in GENEROUS, though 40 have signed agreements with CMS.
Open in Who Shared Issue with article?
See all 987 licensed articles (994 Total)